At the recently concluded 18th CPHI & PMEC India expo in Greater Noida, the Drugs Controller general (DCGI) and senior leadership of CDSCO declared that “India is very well-positioned to evolve into an innovation-led pharmaceutical nation in the next five years.” 

This optimism reflects a broad set of policy, regulatory, and financial initiatives designed to re-engineer India’s pharma ecosystem. Key among them the newly launched government schemes including the hospital-finance initiative reportedly worth ₹1,00,000 crore, and a recommendation for R&D funding totalling around ₹5,000 crore  both aimed at strengthening early-stage innovation, clinical research and domestic drug discovery. 

Regulatory reforms have also been emphasised. According to CDSCO, processes are being streamlined, regulatory layers reduced, and non-serious offences decriminalised  steps intended to lower entry barriers, encourage experimentation, and accelerate approval pipelines for new molecules, biologics and complex drugs. 

Industry veterans at the expo echoed the call: the sector is shifting its core from generics to high-value innovation. Areas such as biosimilars, peptides, next-generation biologics, complex generics, advanced formulations, and drug-delivery systems  including those requiring sophisticated technologies  were highlighted as key growth verticals. to transform India’s role from a global supplier of affordable generics into a globally competitive centre of drug discovery, MedTech-integrated therapies and next-gen pharmaceutical innovation.